<DOC>
	<DOC>NCT00419484</DOC>
	<brief_summary>We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Primary composite endpoints: Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine) Secondary endpoints: urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes HbA1c: more than 7% and less than 9% insulin treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>